Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Raised to $230.00

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price objective boosted by Truist Financial from $220.00 to $230.00 in a report issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the specialty pharmaceutical company’s stock. Truist Financial’s price target would indicate a potential upside of 67.85% from the stock’s previous close.

JAZZ has been the topic of several other reports. HC Wainwright reaffirmed a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Cantor Fitzgerald lowered shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and increased their target price for the stock from $140.00 to $150.00 in a report on Wednesday, February 26th. JPMorgan Chase & Co. boosted their price target on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. TD Cowen cut their price objective on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. Finally, Wells Fargo & Company upgraded shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $130.00 to $170.00 in a report on Thursday, February 13th. Two investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Jazz Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $184.47.

Jazz Pharmaceuticals Price Performance

JAZZ traded down $3.21 during trading on Thursday, reaching $137.03. The stock had a trading volume of 256,010 shares, compared to its average volume of 729,607. Jazz Pharmaceuticals has a one year low of $99.06 and a one year high of $148.06. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The business has a 50-day moving average of $127.64 and a 200-day moving average of $119.71. The stock has a market cap of $8.32 billion, a PE ratio of 19.25, a PEG ratio of 1.04 and a beta of 0.56.

Insiders Place Their Bets

In other news, CEO Bruce C. Cozadd sold 6,500 shares of the business’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $144.25, for a total value of $937,625.00. Following the transaction, the chief executive officer now owns 464,058 shares of the company’s stock, valued at approximately $66,940,366.50. The trade was a 1.38 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Patricia Carr sold 4,813 shares of the business’s stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $144.42, for a total transaction of $695,093.46. Following the completion of the sale, the chief accounting officer now owns 8,237 shares in the company, valued at $1,189,587.54. This represents a 36.88 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 18,113 shares of company stock worth $2,551,834 over the last three months. 4.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in JAZZ. Fuller & Thaler Asset Management Inc. raised its position in Jazz Pharmaceuticals by 117.4% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 939,351 shares of the specialty pharmaceutical company’s stock worth $115,681,000 after purchasing an additional 507,234 shares during the period. Darwin Global Management Ltd. purchased a new position in Jazz Pharmaceuticals during the 4th quarter valued at $59,668,000. Dimensional Fund Advisors LP lifted its position in shares of Jazz Pharmaceuticals by 18.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company’s stock worth $250,619,000 after purchasing an additional 320,724 shares during the last quarter. Ameriprise Financial Inc. boosted its stake in shares of Jazz Pharmaceuticals by 20.9% during the fourth quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company’s stock valued at $225,076,000 after purchasing an additional 315,608 shares during the period. Finally, GMT Capital Corp grew its holdings in shares of Jazz Pharmaceuticals by 140.0% in the fourth quarter. GMT Capital Corp now owns 508,800 shares of the specialty pharmaceutical company’s stock worth $62,659,000 after purchasing an additional 296,800 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.